Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.38 |
| ▸ | CDK9 | P50750 | 6/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30591217 | 1.00 | HTR2A (0.41) | HTR2AHTR2CLRRK2JAK2JAK3 | |
| SCHEMBL30591166 | 0.83 | ALOX5AP (0.37) | PIK3CA | |
| SCHEMBL25599468 | 0.82 | GABRG2 (0.37) | HTR2AHTR2CJAK2PIK3CA | |
| SCHEMBL25599467 | 0.80 | IDO1 (0.39) | PIK3CA | |
| SCHEMBL25599471 | 0.80 | SCN9A (0.35) | JAK2PIK3CA | |
| SCHEMBL30591239 | 0.80 | SCN9A (0.35) | JAK2PIK3CA | |
| SCHEMBL25599470 | 0.76 | SCN9A (0.35) | PIK3CA | |
| SCHEMBL8940603 | 0.71 | ERN1 (0.51) | LRRK2JAK2JAK3CCNT1CDK9 | |
| SCHEMBL30591352 | 0.69 | S1PR1 (0.37) | HTR2AHTR2CLRRK2JAK2JAK3 | |
| SCHEMBL10304909 | 0.67 | S1PR1 (0.46) | LRRK2JAK2JAK3CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| CN-116829559-A | Carbonyl substituted diazaspiro compounds and uses thereof | 烨辉医药科技(上海)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023098876-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS (SHANGHAI) LIMITED (CN) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | HTR2A 3071/4885HTR2C 1821/4885LRRK2 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.